AR062556A1 - Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas - Google Patents
Composiciones farmaceuticas de clonazepam y metodos de uso de las mismasInfo
- Publication number
- AR062556A1 AR062556A1 ARP070103802A ARP070103802A AR062556A1 AR 062556 A1 AR062556 A1 AR 062556A1 AR P070103802 A ARP070103802 A AR P070103802A AR P070103802 A ARP070103802 A AR P070103802A AR 062556 A1 AR062556 A1 AR 062556A1
- Authority
- AR
- Argentina
- Prior art keywords
- solvent
- clonazepam
- soluble
- benzodiazepine
- solvent system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones de benzodiazepina formuladas para la administracion intranasal, que comprenden un sistema binario de disolvente que comprende un primer disolvente en el que la benzodiazepina es soluble, pudiendo penetrar el primer disolvente en el tejido de la mucosa nasal, y un segundo disolvente en el que la benzodiazepina es menos soluble. Las composiciones de la presente pueden usarse para tratar una variedad de trastornos incluyendo, pero sin limitarse a, ataques de pánico, espasmos musculares, ansiedad y convulsiones. En un aspecto, la presente se refiere a una composicion de clonazepam de corta accion para la administracion transnasal que puede utilizarse para el tratamiento de convulsiones repetidas. Reivindicacion 1: Composicion farmacéutica para la administracion transmucosa a un mamífero, que comprende un sistema de disolvente que comprende un primer disolvente en el que el clonazepam es soluble, pudiendo penetrar el primer disolvente en el tejido de la mucosa nasal, y un segundo disolvente en el que el clonazepam es menos soluble que en el primer disolvente, en el que el sistema de disolvente comprende el 10% (peso/peso) o menos de una disolucion tampon acuosa, con la salvedad de que el sistema de disolvente no comprende polímeros de polietilenglicol libres; y una cantidad terapéuticamente eficaz de clonazepam.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84056806P | 2006-08-28 | 2006-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062556A1 true AR062556A1 (es) | 2008-11-19 |
Family
ID=38819711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103802A AR062556A1 (es) | 2006-08-28 | 2007-08-28 | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas |
Country Status (17)
Country | Link |
---|---|
US (2) | US8609651B2 (es) |
EP (2) | EP2068933A2 (es) |
JP (2) | JP2010502614A (es) |
KR (1) | KR20090043603A (es) |
CN (1) | CN101528261B (es) |
AR (1) | AR062556A1 (es) |
AU (1) | AU2007290589B2 (es) |
BR (1) | BRPI0714907A2 (es) |
CA (1) | CA2662197A1 (es) |
IL (1) | IL197275A0 (es) |
MX (1) | MX2009002310A (es) |
NO (1) | NO20091211L (es) |
NZ (2) | NZ575744A (es) |
PE (1) | PE20081361A1 (es) |
TW (1) | TW200824693A (es) |
UY (1) | UY30561A1 (es) |
WO (2) | WO2008027357A2 (es) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US12097176B2 (en) | 2023-11-10 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
CN101678112B (zh) * | 2007-01-19 | 2016-08-31 | 哈南亚有限公司 | 用于递送治疗剂的方法和组合物 |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
GB0716907D0 (en) * | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
WO2009027697A2 (en) * | 2007-08-31 | 2009-03-05 | Archimedes Development Limited | Non-aqueous pharmaceutical compositions |
ES2586032T3 (es) * | 2008-03-28 | 2016-10-11 | Hale Biopharma Ventures, Llc | Administración de composiciones de benzodiazepinas |
KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
CA2760451A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Compositions and methods for treating and preventing overactive bladder and conditions associated therewith |
WO2010126970A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Methods for treating and preventing erectile dysfunction |
GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
KR20140029426A (ko) * | 2011-03-31 | 2014-03-10 | 아코르다 쎄라퓨틱스 인코포레이티드 | 비강내 벤조디아제핀 약제학적 조성물 |
ES2917973T3 (es) | 2011-06-14 | 2022-07-12 | Neurelis Inc | Administración de benzodiacepina |
US9795559B2 (en) * | 2011-12-11 | 2017-10-24 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
US20160000702A1 (en) * | 2013-02-22 | 2016-01-07 | Eastgate Pharmaceuticals Inc. | Pharmaceutical composition for enhanced transmucosal adminstration of benzodiazepines |
KR101635635B1 (ko) * | 2014-12-04 | 2016-07-01 | 주식회사 엘지생활건강 | 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물 |
US20180104366A1 (en) | 2015-05-25 | 2018-04-19 | Isotherapeutics Group, Llc | Dotmp kit formulations for radioisotopes |
US20200390754A1 (en) * | 2017-11-17 | 2020-12-17 | Neurana Pharmaceuticals, Inc. | Methods of administering tolperisone |
WO2019136308A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
US10896106B2 (en) * | 2018-05-10 | 2021-01-19 | Teradyne, Inc. | Bus synchronization system that aggregates status |
US20200338090A1 (en) * | 2019-04-29 | 2020-10-29 | Marsh and Wang Medical Systems, LLC | Seizure control compositions and methods of using same |
CN110420190B (zh) * | 2019-08-29 | 2021-07-09 | 湖南洞庭药业股份有限公司 | 氯硝西泮片及其制备方法 |
KR20240017955A (ko) * | 2021-06-10 | 2024-02-08 | 뉴렐리스 인코포레이티드 | 소아 환자의 발작 장애를 치료하기 위한 방법 및 조성물 |
CN114656410A (zh) * | 2022-03-02 | 2022-06-24 | 济南同路医药科技发展有限公司 | 一种氯硝西泮杂质及其制备方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266466A (en) * | 1987-01-14 | 1993-11-30 | President And Fellows Of Harvard College | Method of using T7 DNA polymerase to label the 3' end of a DNA molecule |
SE8800080L (sv) | 1988-01-13 | 1989-07-14 | Kabivitrum Ab | Laekemedelskomposition |
US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
FR2656303B1 (fr) | 1989-12-26 | 1994-06-10 | Parke Davis | Solution buvable d'un derive des benzodiazepines et son application pharmacologique. |
DE69129110T2 (de) | 1990-05-10 | 1998-12-10 | Bechgaard International Research And Development A/S, Hellerup | Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole |
DE4021263C2 (de) * | 1990-07-04 | 1996-04-11 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
FR2692174B1 (fr) | 1992-06-16 | 1994-08-19 | Valois | Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide. |
DK17093D0 (da) | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
AU2345695A (en) * | 1994-04-28 | 1995-11-29 | F. Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
GB9409778D0 (en) * | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
DE19756442A1 (de) * | 1997-12-18 | 1999-06-24 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
US6699849B1 (en) * | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
KR100715513B1 (ko) * | 1999-07-26 | 2007-05-08 | 에스케이 코오포레이션 | 경비 항경련성 조성물 |
DE19938798A1 (de) * | 1999-08-16 | 2001-03-01 | Pfeiffer Erich Gmbh & Co Kg | Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte |
DE19940236A1 (de) * | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
US6610271B2 (en) * | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
FR2815611B1 (fr) | 2000-10-23 | 2003-04-11 | Valois Sa | Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution |
US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
US7262185B2 (en) * | 2001-08-08 | 2007-08-28 | Takeda Chemical Industries Ltd. | Benzazepine derivative, process for producing the same, and use |
CN1642576A (zh) | 2002-02-25 | 2005-07-20 | 药物发展有限公司 | 吸收增强剂 |
US6742677B2 (en) | 2002-04-18 | 2004-06-01 | Valois S.A.S. | Fluid dispenser pump |
BR0311530A (pt) * | 2002-05-23 | 2005-05-10 | Umd Inc | Compostos e método de liberação para droga transmucosal e para crio-proteção |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
ITRM20020357A1 (it) | 2002-07-03 | 2004-01-05 | Foscama Biomed Chim Farma | Composizione liquida per la somministrazione orale di lorazepam. |
PL211224B1 (pl) | 2003-01-31 | 2012-04-30 | Orexo Ab | Kompozycja farmaceutyczna do leczenia ostrych zaburzeń przez podjęzykowe lub donosowe podawanie oraz jej zastosowanie |
CA2529489C (en) | 2003-06-17 | 2012-01-03 | Sk Corporation | Transnasal microemulsions containing diazepam |
PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
PL1848403T3 (pl) | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
US20070021411A1 (en) * | 2005-05-11 | 2007-01-25 | Cloyd James C | Supersaturated benzodiazepine solutions and their delivery |
TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
US9319244B2 (en) | 2010-12-22 | 2016-04-19 | Usablenet Inc. | Methods for emailing labels as portable data files and devices thereof |
-
2007
- 2007-08-14 TW TW096130010A patent/TW200824693A/zh unknown
- 2007-08-23 PE PE2007001144A patent/PE20081361A1/es not_active Application Discontinuation
- 2007-08-27 AU AU2007290589A patent/AU2007290589B2/en not_active Ceased
- 2007-08-27 US US11/897,028 patent/US8609651B2/en not_active Expired - Fee Related
- 2007-08-27 WO PCT/US2007/018877 patent/WO2008027357A2/en active Application Filing
- 2007-08-27 NZ NZ575744A patent/NZ575744A/en not_active IP Right Cessation
- 2007-08-27 CA CA002662197A patent/CA2662197A1/en not_active Abandoned
- 2007-08-27 EP EP07837400A patent/EP2068933A2/en not_active Withdrawn
- 2007-08-27 KR KR1020097006303A patent/KR20090043603A/ko not_active Application Discontinuation
- 2007-08-27 JP JP2009526683A patent/JP2010502614A/ja not_active Ceased
- 2007-08-27 MX MX2009002310A patent/MX2009002310A/es not_active Application Discontinuation
- 2007-08-27 WO PCT/US2007/018942 patent/WO2008027395A2/en active Application Filing
- 2007-08-27 NZ NZ595388A patent/NZ595388A/en not_active IP Right Cessation
- 2007-08-27 CN CN2007800399467A patent/CN101528261B/zh not_active Expired - Fee Related
- 2007-08-27 BR BRPI0714907-7A patent/BRPI0714907A2/pt not_active IP Right Cessation
- 2007-08-27 US US11/897,002 patent/US8716279B2/en not_active Expired - Fee Related
- 2007-08-27 UY UY30561A patent/UY30561A1/es unknown
- 2007-08-27 EP EP07811570A patent/EP2056877A2/en not_active Withdrawn
- 2007-08-27 JP JP2009526675A patent/JP2010502612A/ja not_active Ceased
- 2007-08-28 AR ARP070103802A patent/AR062556A1/es not_active Application Discontinuation
-
2009
- 2009-02-26 IL IL197275A patent/IL197275A0/en unknown
- 2009-03-23 NO NO20091211A patent/NO20091211L/no not_active Application Discontinuation
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US12097175B2 (en) | 2023-09-14 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US12097176B2 (en) | 2023-11-10 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
Publication number | Publication date |
---|---|
WO2008027357A9 (en) | 2009-04-30 |
NO20091211L (no) | 2009-05-27 |
AU2007290589B2 (en) | 2012-04-05 |
NZ595388A (en) | 2011-12-22 |
CN101528261B (zh) | 2012-07-18 |
EP2056877A2 (en) | 2009-05-13 |
US20080070904A1 (en) | 2008-03-20 |
NZ575744A (en) | 2011-10-28 |
WO2008027357A3 (en) | 2008-04-17 |
US8716279B2 (en) | 2014-05-06 |
US8609651B2 (en) | 2013-12-17 |
IL197275A0 (en) | 2009-12-24 |
AU2007290589A1 (en) | 2008-03-06 |
JP2010502614A (ja) | 2010-01-28 |
US20080076761A1 (en) | 2008-03-27 |
PE20081361A1 (es) | 2008-11-06 |
TW200824693A (en) | 2008-06-16 |
CN101528261A (zh) | 2009-09-09 |
EP2068933A2 (en) | 2009-06-17 |
WO2008027357A2 (en) | 2008-03-06 |
MX2009002310A (es) | 2009-09-21 |
KR20090043603A (ko) | 2009-05-06 |
CA2662197A1 (en) | 2008-03-06 |
WO2008027395A3 (en) | 2008-04-17 |
JP2010502612A (ja) | 2010-01-28 |
BRPI0714907A2 (pt) | 2014-08-19 |
WO2008027395A2 (en) | 2008-03-06 |
UY30561A1 (es) | 2008-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062556A1 (es) | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas | |
NO20053277D0 (no) | Hurtigvirkende farmasoytisk sammensetning. | |
BRPI1014783A2 (pt) | formulações farmacêuticas e métodos para tratar infecções do trato respiratório | |
EA200701511A1 (ru) | Фармацевтические композиции бендамустина, предназначенные для лиофилизации | |
CR10166A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania | |
BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
BRPI0709581A8 (pt) | compostos de bicicloeteroarila como moduladores de px27 e seu uso | |
AR063201A1 (es) | Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas | |
EA200801698A1 (ru) | Лекарственные композиции для применения в вагине | |
AR049063A1 (es) | Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas | |
AR054371A1 (es) | Metodos y composiciones para manejo de desordenes psicoticos | |
BRPI0822162B8 (pt) | composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal | |
EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
CL2009002183A1 (es) | Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica. | |
CO6321221A2 (es) | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal | |
MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
CL2017001913A1 (es) | Composición tópica curativa | |
CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids | |
CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
AR058298A1 (es) | Composicion veterinaria | |
EA201992759A1 (ru) | Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения | |
ECSP088545A (es) | Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales | |
UY31826A (es) | Compuesto peptídico y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |